Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 10.44M P/E - EPS this Y 93.40% Ern Qtrly Grth -
Income -149.01M Forward P/E -0.23 EPS next Y -115.00% 50D Avg Chg -40.00%
Sales 12.46M PEG - EPS past 5Y - 200D Avg Chg -69.00%
Dividend N/A Price/Book 0.06 EPS next 5Y - 52W High Chg -91.00%
Recommedations 2.00 Quick Ratio 0.34 Shares Outstanding 139.99M 52W Low Chg 2.00%
Insider Own 0.21% ROA -51.72% Shares Float 22M Beta 2.10
Inst Own 0.29% ROE -163.24% Shares Shorted/Prior 467.19K/1.30M Price 1.01
Gross Margin 21.59% Profit Margin - Avg. Volume 395,326 Target Price 21.00
Oper. Margin -831.48% Earnings Date Nov 7 Volume 677,560 Change -1.94%
About Tonix Pharmaceuticals Holding C

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Tonix Pharmaceuticals Holding C News
08:00 AM Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia
12/17/24 Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia
12/16/24 Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights
12/09/24 Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers
12/03/24 Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires
12/03/24 TNXP: NDA Filed for TNX-102 SL in Fibromyalgia…
11/26/24 Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference
11/18/24 Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual
11/18/24 Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting
11/14/24 Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments
11/13/24 Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting
11/13/24 Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company’s Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals
11/05/24 Tonix Pharma Partners for Vaccine Clinical Trial
11/04/24 Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya
11/01/24 Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024
10/29/24 Tonix Pharmaceuticals to Present at BIO-Europe® 2024
10/25/24 Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference
10/24/24 Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024
10/17/24 Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA)
10/16/24 Empery Asset Management LP Acquires Shares in Tonix Pharmaceuticals
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
LEDERMAN SETH Chief Executive Offi.. Chief Executive Officer Mar 25 Buy 0.245 100,000 24,500 112,177 03/28/22